What one share of Kala Bio holds
We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome (“MSC-S”) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.
Kala Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.31 |
|---|---|
| Cash and investments | $0.01 |
| Debt | $1.39 |
| Book value | $0.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$6,236 | $147.46 | −$5,205 | — | $7,750 |
| 2019 | $443.88 | −$6,895 | $97.56 | −$6,873 | — | $2,057 |
| 2020 | $303.66 | −$4,980 | — | — | — | $4,243 |
| 2021 | $426.89 | −$5,416 | — | — | — | $635.33 |
| 2022 | $127.97 | −$1,474 | — | — | — | $555.78 |
| 2023 | $0.00 | −$867.58 | — | — | — | $135.97 |
| 2024 | $0.00 | −$507.25 | — | — | — | $101.23 |
| 2025 | $0.00 | −$165.56 | — | — | — | $12.56 |
Common questions about Kala Bio
How much does one share of Kala Bio earn?
Over the last 12 months, Kala Bio lost $1.31 for each share.
Does Kala Bio pay a dividend?
Kala Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kala Bio’s book value per share?
Kala Bio’s book value is $0.47 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Kala Bio have?
Each share of Kala Bio has $0.01 of cash and investments and $1.39 of debt, as of June 30, 2026.
Has Kala Bio bought back shares?
Kala Bio’s share count rose about 1423% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.